Related Experiment Videos
Inflammatory Bowel Disease in Children
Mihaela Ringheanu1, James Markowitz
1Division of Pediatric Gastroenterology and Nutrition, North Shore- Long Island Jewish Health System, 300 Community Drive, Manhasset, NY 11030, USA. jamesm@nshs.edu
Insights
Treating Crohn's disease and ulcerative colitis in children involves symptom reduction, nutritional support, and growth optimization. Effective management combines nutritional and pharmacologic therapies to induce and maintain remission, with emerging treatments offering future hope.
Area of Science:
- Pediatric Gastroenterology
- Inflammatory Bowel Disease Research
- Clinical Therapeutics
Background:
- Crohn's disease (CD) and ulcerative colitis (UC) are chronic, incurable inflammatory bowel diseases (IBD) causing significant morbidity in children.
- Current treatment goals include symptom control, nutritional optimization, normal growth, complication prevention, and minimizing psychologic impact.
Purpose of the Study:
- To outline optimal treatment strategies for pediatric CD and UC, focusing on inducing and maintaining clinical remission.
- To discuss the roles of nutritional therapy, pharmacologic agents, and surgery in managing these conditions in children.
Main Methods:
- Review of current therapeutic approaches for pediatric CD and UC.
- Analysis of pharmacologic agents including corticosteroids, infliximab, 6-mercaptopurine (6-MP), azathioprine (AZA), and 5-aminosalicylates (5-ASA).
- Evaluation of nutritional interventions like enteral nutrition and the role of surgery.
Main Results:
- Combination therapy (nutritional and pharmacologic) is optimal for most pediatric CD cases.
- Potent immunomodulatory therapy (corticosteroids, infliximab) combined with 6-MP/AZA is effective for moderate-to-severe CD remission.
- Nutritional therapy can induce remission in CD, but relapse is common, necessitating pharmacologic support. Mild UC responds to 5-ASA; severe UC requires potent immunomodulators to avoid colectomy.
Conclusions:
- Optimizing pediatric IBD treatment requires a multifaceted approach combining nutrition, pharmacotherapy, and potentially surgery.
- Monitoring 6-MP/AZA metabolite levels aids in optimizing therapy and minimizing toxicity.
- Emerging biologic and probiotic therapies hold promise for improved future treatments for pediatric IBD.
Abstract:
Crohn's disease and ulcerative colitis remain medically incurable conditions with potentially significant morbidity. The treatment of children with these conditions therefore should seek to reduce or eliminate symptoms, optimize nutritional status, promote normal growth and development, prevent complications, and minimize the potential psychologic effects of chronic illness. Treatment strategies must seek to both induce and maintain clinical remission. For all but the most mildly affected children with Crohn's disease, a combination of nutritional and pharmacologic approaches is optimal. For those with ulcerative colitis, anti-inflammatory medication is necessary. Moderate to severe Crohn's disease acutely responds best to potent immunomodulatory therapy, eg, corticosteroids and infliximab. Either agent must be coupled with 6-mercaptopurine or azathioprine to maintain long-term remission and to minimize toxicity. Particular attention must be paid to limit the growth suppression and other toxic effects of corticosteroids. Elemental or semielemental enteral nutrition also can induce remission effectively, but relapse is common after primary nutritional therapy is discontinued, mandating concomitant pharmacologic therapy with either 6-mercaptopurine or azathioprine. The availability of 6-mercaptopurine/azathioprine metabolite testing allows optimization of immunomodulatory therapy, detection of noncompliance, and avoidance of potentially dangerous toxicity. Mild ulcerative colitis acutely responds to treatment with a 5-aminosalicylate medication. Long-term remission frequently can be maintained with the same medication. Moderate to severe disease activity requires potent immunomodulatory therapy if colectomy is to be avoided. Surgery is a potential cure for patients with ulcerative colitis, although the development of pouchitis after ileal pouch anal anastomosis is common and frequently requires long-term medical management. Surgery provides only palliative relief of complications in those with Crohn's disease. Emerging therapies, especially evolving biologic and probiotic agents, offer hope for better treatments in the years ahead.